UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

Palmer, DH; Ma, YT; Peck-Radosavljevic, M; Ross, P; Graham, J; Fartoux, L; Deptala, A; ... Meyer, T; + view all (2018) A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer , 118 pp. 1162-1168. 10.1038/s41416-018-0051-8. Green open access

[thumbnail of Article]
Preview
Text (Article)
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.pdf - Published Version

Download (805kB) | Preview
[thumbnail of Supplementary Data]
Preview
Text (Supplementary Data)
Meyer_41416_2018_51_MOESM1_ESM.pdf

Download (149kB) | Preview
[thumbnail of Supplementary Figure S1Supplementary Figure S2]
Preview
Image (Supplementary Figure S1Supplementary Figure S2)
Meyer_41416_2018_51_MOESM2_ESM.tif

Download (1MB) | Preview
[thumbnail of Supplementary Figure S2]
Preview
Image (Supplementary Figure S2)
Meyer_41416_2018_51_MOESM3_ESM.tif

Download (763kB) | Preview
[thumbnail of Supplementary Figure S3]
Preview
Image (Supplementary Figure S3)
Meyer_41416_2018_51_MOESM4_ESM.tif

Download (414kB) | Preview
[thumbnail of Supplementary Table S1]
Preview
Text (Supplementary Table S1)
Meyer_41416_2018_51_MOESM5_ESM.pdf

Download (179kB) | Preview
[thumbnail of Supplementary Table S2]
Preview
Text (Supplementary Table S2)
Meyer_41416_2018_51_MOESM6_ESM.pdf

Download (20kB) | Preview
[thumbnail of Supplementary Table S3]
Preview
Text (Supplementary Table S3)
Meyer_41416_2018_51_MOESM7_ESM.pdf

Download (107kB) | Preview
[thumbnail of Supplementary Table S4]
Preview
Text (Supplementary Table S4)
Meyer_41416_2018_51_MOESM8_ESM.pdf

Download (135kB) | Preview
[thumbnail of Supplementary Table S5]
Preview
Text (Supplementary Table S5)
Meyer_41416_2018_51_MOESM9_ESM.pdf

Download (20kB) | Preview
[thumbnail of Supplementary Table S6]
Preview
Text (Supplementary Table S6)
Meyer_41416_2018_51_MOESM10_ESM.pdf

Download (16kB) | Preview
[thumbnail of Supplementary Table S7]
Preview
Text (Supplementary Table S7)
Meyer_41416_2018_51_MOESM11_ESM.pdf

Download (60kB) | Preview
[thumbnail of Supplementary Table S8]
Preview
Text (Supplementary Table S8)
Meyer_41416_2018_51_MOESM12_ESM.pdf

Download (196kB) | Preview
[thumbnail of Supplementary Table S9]
Preview
Text (Supplementary Table S9)
Meyer_41416_2018_51_MOESM13_ESM.pdf

Download (255kB) | Preview

Abstract

BACKGROUND: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with unresectable advanced hepatocellular carcinoma (aHCC). METHODS: Phase I: Patients were stratified into two groups per baseline aminotransferase/alanine aminotransferase and Child-Pugh score; MTD was determined. Phase II: Patients were randomised 2:1 to nintedanib (MTD) or sorafenib (400-mg bid) in 28-day cycles until intolerance or disease progression. Time-to-progression (TTP, primary endpoint), overall survival (OS) and progression-free survival (PFS) were determined. RESULTS: Phase-I: no DLTs observed; nintedanib MTD in both groups was 200 mg bid. Phase-II: patients (N = 93) were randomised to nintedanib (n = 62) or sorafenib (n = 31); TTP was 5.5 vs. 4.6 months (HR = 1.44 [95% CI, 0.81-2.57]), OS was 11.9 vs. 11.4 months (HR = 0.88 [95% CI, 0.52-1.47]), PFS was 5.3 vs. 3.9 months (HR = 1.35 [95% CI, 0.78-2.34]), respectively (all medians). Dose intensity and tolerability favoured nintedanib. Fewer patients on nintedanib (87.1%) vs. sorafenib (96.8%) had drug-related adverse events (AEs) or grade ≥ 3 AEs (67.7% vs. 90.3%), but more patients on nintedanib (28 [45.2%]) had AEs leading to drug discontinuation than did those on sorafenib (7 [22.6%]). CONCLUSIONS: Nintedanib may have similar efficacy to sorafenib in aHCC.

Type: Article
Title: A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/s41416-018-0051-8
Publisher version: https://doi.org/10.1038/s41416-018-0051-8
Language: English
Additional information: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10045800
Downloads since deposit
187Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item